Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina S. Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina Chiara Garassino, John V. Heymach, Mark A. Socinski, Szu‐Yun Leu, Gajanan Bhat, François Lebel, Xiuning Le
Topics & Concepts
MedicineOpen labelExonCohortOncologyInternal medicineCancer researchClinical trialGeneGeneticsBiologyLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies